‘The Food and Drug Administration (FDA) has given GlaxoSmithKilne (GSK) their approval of the MenHibrix vaccine(MHV), which is meant for infants between the ages of 6 weeks to 18 months. This vaccine is a dangerous mixture of the meningococcal disease and Hib disease. MHV will be manufactured in Rixensart, a Belgium-based arm of GSK Biologicals.
In 2010 and 2011, the FDA rejected MHV. GSK claims that they have “resolved” the FDA’s concerns about the necessity, potency and efficiency of MHV. This simply accepted GSK’s word that they have taken care of the vaccine’s issues. The FDA does not require more proof than that.’